AI assistant
Sending…
Climb Bio, Inc. — Director's Dealing 2024
Jul 17, 2024
33982_dirs_2024-07-16_b3ff80cb-c4b1-469b-8831-02b9850d418a.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Eliem Therapeutics, Inc. (ELYM)
CIK: 0001768446
Period of Report: 2024-07-12
Reporting Person: Morisset Valerie (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-07-12 | Common Stock | S | 50000 | $7.07 | Disposed | 294683 | Direct |
| 2024-07-15 | Common Stock | S | 42377 | $7.01 | Disposed | 252306 | Direct |
More from Climb Bio, Inc.
Regulatory Filings
2026
May 29
Interim / Quarterly Report
2026
May 7
Regulatory Filings
2026
May 7
Regulatory Filings
2026
May 5
Capital/Financing Update
2026
Apr 28
Board/Management Information
2026
Apr 3
Director's Dealing
2026
Feb 27
Major Shareholding Notification
2026
Feb 17
Director's Dealing
2026
Feb 17
Director's Dealing
2026
Jan 8